An integrative network medicine approach identifies Erlotinib as a repurposed therapeutic candidate for obesity
This study establishes a cell-type-specific integrative network medicine framework that identifies and validates the repurposed anticancer drug Erlotinib as a potential therapeutic candidate for obesity by targeting BMP2K to modulate lipid metabolism and inflammation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Obesity is more than just an excess of weight; it is a complex state where the body's fat tissues stop working correctly. Inside these tissues, tiny cells that store energy and cells that fight infection begin to malfunction, creating a low-level, chronic fire of inflammation that disrupts how the body handles sugar and fat. For decades, scientists have tried to find drugs to fix this, but creating new medicines from scratch is slow, expensive, and often fails. A different strategy has emerged called drug repurposing. Instead of inventing a new molecule, researchers look at medicines already approved for other diseases, such as cancer or heart conditions, to see if they might work for obesity. This approach is faster because the safety of the drug is already known. The challenge, however, has been figuring out exactly which cells in the body a drug should target, as the human body is made of thousands of different cell types that behave differently depending on where they are located.
A team of researchers at Hunan Normal University and Henan University of Chinese Medicine tackled this problem by building a detailed map of the fat tissue in people with obesity. They did not just look at the tissue as a whole; they used a high-resolution technique to examine individual cells, separating them into groups based on their specific jobs. They focused on two main areas of fat: the fat stored just under the skin and the fat deep inside the belly, which is more closely linked to health risks. By combining this cellular map with large genetic studies of obesity, they identified four specific groups of cells that were behaving abnormally in obese individuals. These groups included fat-storing cells and immune cells in both the under-skin and belly fat. The researchers then used computer models to trace how these cells talked to one another and which genes were driving their dysfunction.
Using this detailed network, the team ran a search to find existing drugs that could interrupt these harmful signals. The computer analysis pointed to a drug called Erlotinib. Erlotinib is already approved to treat certain types of cancer by blocking a specific protein that helps tumors grow. The researchers found that the same protein, and others related to it, were also active in the fat cells of obese people. To be sure this connection was real and not just a coincidence, they used a statistical method that looks at genetic data to see if changes in these proteins actually cause obesity. The results supported the idea that targeting these proteins could help. They then used computer simulations to check if the Erlotinib molecule could physically fit and bind to the specific proteins inside the fat cells, finding that it did so with strong stability.
To test if this idea worked in a living system, the researchers turned to zebrafish, a small fish often used in medical research because their bodies respond to drugs in ways similar to humans. They fed the fish a high-fat diet to make them obese, then gave them Erlotinib. The fish treated with the drug gained significantly less weight than the untreated obese fish, and their body measurements improved. Inside their bodies, the drug lowered the levels of triglycerides, a type of fat in the blood, and reduced the expression of genes that tell the body to store more fat. It also calmed down the genes responsible for inflammation. The study also identified a specific protein called BMP2K, which was found to be elevated in the obese fish and reduced by the drug, suggesting this protein might be a key part of how the drug works.
The researchers concluded that Erlotinib shows promise as a treatment for obesity, not because it is a new invention, but because it targets the specific cellular machinery that goes wrong in the disease. While the drug is currently used for cancer, this study suggests it could be repurposed to help manage weight and metabolism. The team emphasized that their findings are based on computer models and animal tests, and that the drug's effects in humans would need to be confirmed in future clinical trials. Nevertheless, the work provides a clear example of how looking at the body at the level of individual cells can reveal new ways to use old medicines, offering a potential path forward for a condition that affects millions of people worldwide.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.